A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Food Effect After Single and Multiple Oral Doses of ARTS-011 In Chinese Health Subjects
Latest Information Update: 23 Jul 2024
At a glance
- Drugs ARTS 011 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allorion Therapeutics
Most Recent Events
- 20 Feb 2024 New trial record